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CC BY-NC-ND license (http://creativAbstract We measured the serum levels of 8-hydroxydeoxyguanosine (8-OHdG) and investi-
gated whether these levels correlate with incidence of ischemic cardiomyopathy (ICM), and
whether these levels correlate with underlying oxidative stress in patients with ICM. Polymer-
ase chain reaction-restriction fragment length polymorphism analysis was performed to assess
the prevalence of the Ser/Cys polymorphism in the human 8-oxoguanine glycosylase (hOGG1)
gene. We analyzed the samples from 246 ICM cases (the ICM group) and another 246 age- and
sex-matched volunteers with normal coronary artery function (the control group). Levels of 8-
OHdG in participants’ blood samples were 6.7  1.7 and 3.0  0.8 in the ICM and control
groups, respectively (p < 0.05). Although there were no differences in allele frequency
(p Z 0.140), significant differences were present in the genotype distributions (p Z 0.002).
The Cys/Cys genotype correlated strongly with the risk of developing ICM (odds ratio, 2.2;
95% confidence interval, 1.4e3.3). Treating the Ser/Ser and Ser/Cys genotypes as members
of the same group increased the predicted ICM risk for patients carrying the Cys/Cys genotype
(odds ratio, 1.9; 95% confidence interval, 1.2e2.9). The serum level of 8-OHdG in the ICM group
was higher than that in the control group (p < 0.05) and significantly increased in thoseeclare no conflicts of interest.
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242 Y. Jin et al.carrying the Cys/Cys genotype (8.7  1.7 for the Cys/Cys group, and 4.5  0.8 for the Ser/
SerþSer/Cys group; p < 0.05). Patients carrying the Cys/Cys genotype had a significantly
increased risk of developing ICM. Serum levels of 8-OHdG were significantly increased in pa-
tients with ICM.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Ischemic cardiomyopathy (ICM) is a common type of dilated
cardiomyopathy caused by coronary atherosclerotic heart
disease (CHD). ICM manifests as systolic or diastolic
dysfunction, with clinical symptoms not entirely explained
by coronary artery disease, such as arrhythmia, heart
dilatation or stiffness, heart failure, and other manifesta-
tions of severe ischemia. Long-term myocardial ischemia
can lead to either local or diffuse myocardial fibrosis,
resulting in systolic or diastolic dysfunction. Clinical treat-
ment remains challenging owing to a lack of specific ther-
apeutic interventions. The literature increasingly suggests
that ICM is a disease with both genetic and environmental
causes. The role of oxidative stress, as well as the expres-
sion levels and polymorphisms of genes encoding DNA-
repair enzymes, are gaining increasing attention. The
pathogenesis of ICM has not been fully elucidated. Many
hypotheses have been advanced to account for the devel-
opment of ICM; among them are genetic polymorphisms,
genetic susceptibility to CHD, oxidative stress, and DNA
damage [1].
Harmful physicochemical factors in the environment,
along with certain in vivo metabolites, can damage DNA.
This damage can lead to mismatching of base pairs during
the cell cycle. However, an in vivo DNA repair system [2]
maintains the integrity and stability of genetic informa-
tion. More than 130 gene products are involved in DNA
repair in humans, including 8-oxoguanine glycosylase
(hOGG1), xeroderma pigmentosum group D-complementing
protein (XPD), and X-ray repair cross-complementing pro-
tein 1 (XRCC1). Oxoguanine glycosylase, encoded by
hOGG1, is a bifunctional DNA glycosylase involved in base
excision and repair [3]. The main function of
oxoguanine glycosylase is to identify and excise 8-
hydroxydeoxyguanosine (8-OHdG) lesions from double-
stranded DNA [4e6]. The hOGG1Ser326Cys polymorphism,
located at base 1245, in the seventh exon of hOGG1dthe
326th codondencodes either cysteine (Cys) or serine (Ser)
[7]. The resulting protein variants exhibit differing enzy-
matic activities, which might be an issue for individuals
with increased levels of oxidative damage. The biomarker
8-OHdG arises from oxidative damage to DNA; measure-
ments of this compound are commonly used as proxies for
levels of oxidative stress [8e10]. To explore the roles of
genetic susceptibility and oxidative stress as possible fac-
tors in ICM pathogenesis, we investigated the correlationsbetween hOGG1 Ser326Cys polymorphism, serum 8-OHdG
levels, and ICM incidence.Methods
Patients
A patient-controlled comparison study was performed in
the Cardiology Department of Wuhan General Hospital,
Guangzhou Military Command, Wuhan, Chain. This study
sampled 246 patients with confirmed ICM, who were hos-
pitalized between June 2010 and June 2014. These patients
(the ICM group) consisted of 158 males (64.2%) and 88 fe-
males (35.8%), aged 40e70 years (mean age,
57.9  10.0 years). From residents of the hospital’s local
area, we selected a “1:1” control group, with the same sex
and age ratio as the ICM group. This control group consisted
of 246 patients, including 160 males (65.0%) and 86 females
(35.0%) aged 40e68 years (mean age, 56.3  10.0 years),
who exhibited normal coronary artery function upon coro-
nary angiography and had been hospitalized during the
same period. All patients in the present study belong to the
Han ethnic group, and their ancestral origins are in the
northern regions of Henan Province. All of the participants
provided written informed consent, and the Medical Ethics
Committee of the hospital approved the present study. This
study adopted the functional classification system of the
New York Heart Association. A key to the diagnostic criteria
is provided below.Diagnosis of ICM
(1) The patient presents clear CHD symptoms. These
symptoms include angina pectoris, myocardial
infarction, or coronary angiography-confirmed artery
stenosis in > 50% of the anterior descending branch,
circumflex branch, and one or more right branches.
(2) To judge coronary angiographies, we performed left
and right coronary angiographies under the conven-
tional projection position. Quantitative analysis of
coronary artery stenosis was performed using the
angiographic image processing system.
(3) The patient’s left ventricular end-diastolic diameter
exceeds 50 mm, and the left ventricular ejection
fraction is < 45%.
Table 1 Comparison of general clinical data between the
two groups (x  s).
Item ICM (n Z 246) Control (n Z 246)
Males 158 (64.2) 160 (65.0)
Age (y) 57.9  10.0 56.3  10.0
SBP (mmHg) 135.9  21.2 133.7  17.1
DBP (mmHg) 83.0  11.5 80.4  11.1
Diabetes 47 (19.1)* 30 (12.2)
Smoking 105 (42.7)* 59 (24.0)
Drinking 80 (32.5) 83 (33.7)
Family history 60 (24.4)* 31 (12.6)
BMI (kg/m2) 24.5  2.7 24.2  2.6
Data are presented as n (%) or mean  standard deviation.
* Compared with the control group, p < 0.05.
BMI Z body mass index; DBP Z diastolic blood pressure;
ICMZ ischemic cardiomyopathy; SBPZ systolic blood pressure.
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(1) The patient has CHD accompanied with a ventricular
septal defect, a ventricular aneurysm, severe mitral
regurgitation, cardiac arrhythmia-caused congestive
heart failure, or another reason for heart dilatation
or failure.
(2) The patient has clearly diagnosed chronic inflamma-
tion, vasculitis, active infections in other parts, liver
disease, autoimmune disease, thyroid disease,
stroke, kidney failure, or lung disease.
Collection of general clinical data and laboratory
detection of 8-OHdG
General clinical data were recorded for each participant,
including: sex, age, blood pressure, diabetes, smoking or
drinking status, family history, and body mass index. Blood
pressure was measured three times on three different
mornings, under quiescent conditions;we recorded themean
value. For blood-collection purposes, all patients were de-
nied access to both alcohol and a high-fat diet for 24 hours.
Twelve hours into the fast, 8 mL of nonanticoagulated blood
was sampled from the cubital vein. The blood was centri-
fuged within 1 h at 3000 rpm for 20 min, and the serum was
separated. Prior to storage, we took aliquots of serum for
biochemical analysis; these analyses determined levels of
total cholesterol (TC), triglycerides (TG), high-density lipo-
protein cholesterol (HDL-C), low-density lipoprotein choles-
terol (LDL-C), uric acid (UA), creatinine (Cr), fasting blood
glucose (FBG), and high-sensitivity C-reactive protein (hs-
CRP). Analyses also detected levels of 8-OHdG and other
biochemical parameters. Detection of serum 8-OHdG relied
on a sandwich enzyme-linked immunosorbent assay, used a
commercial kit (Trevigen, Gaithersburg, MD, USA), and fol-
lowed the kit instructions. We also extracted DNA from these
partial blood samples.
Amplification of the hOGG1 gene fragment
We detected polymorphisms in the hOGG1 gene using poly-
merase chain reaction-restriction fragment length poly-
morphism (PCR-RFLP). Two milliliters of each peripheral
venous blood sample was placed into an EDTA-
anticoagulation tube for leukocyte DNA extraction, using a
commercial kit (Tianwei Times Technology, Beijing, China).
The oligonucleotide primers used in this reaction were 5ʹ-
GGAAGGTGCTTGGGGAAT-3ʹ and 5ʹ-ACTGTCACTAGTCTCAC-
CAG-3ʹ. The reactions were performed using an MJ PTC-220
PCR instrument (MJ Research Inc., Watertown, MA, USA).
The PCR volumes were 25 mL; each vessel contained 50 ng of
Taq polymerase, 10mM TriseHCl, 50mM KCl, 1mM MgCl2, and
0.2mM of each dNTP. We used the following thermocycling
protocol: hot start denaturation at 94C for 3 minutes, fol-
lowed by 35 cycles of denaturation at 94C for 30 seconds,
annealing at 52C for 30 seconds, and extension at 72C for
1 minute. The extension time at 72C was increased to 5 mi-
nutes for the final round. All PCR productswere digestedwith
Fnu4HI endonuclease (Thermo Fisher Scientific, Inc., Wal-
tham, MA, USA) at 37C for 12 hours. Agarose gel electro-
phoresis (3%w/v, containing 0.5mg/L ethidiumbromide)wasfollowed by ultraviolet spectrophotometry, which was used
to inspect the results.
Statistical analysis
For statistical analysis, we used the SPSS version 10.0
software (SPSS Inc., Chicago, IL, USA). Qualitative data
were expressed as percentages, and quantitative data are
expressed as means  standard deviations (x  s). Inter-
group continuous variables were compared using analysis of
variance, or using independent sample t tests. Intergroup
frequencies were compared using Chi-square tests. Multi-
variate logistic regression analysis was used to control for
the influence of confounding factors. The genotype fre-
quency and allele frequency in each group was calculated,
and a HardyeWeinberg equilibrium test was performed to
assess whether the data met HardyeWeinberg equilibrium
conditions. Odds ratio (OR) and 95% confidence interval (CI)
values were calculated to assess the risk of developing ICM;
p < 0.05 was considered statistically significant.
Results
General clinical data
Diabetes, a history of smoking, and a family history of CHD
were significantly more prevalent in the ICM group than
these features were in the control group (p < 0.05). In
addition, ICM group levels of LDL-C, FBG, CRP, and 8-OHdG
were significantly higher than corresponding levels in the
control group. Differences in sex, age, systolic blood pres-
sure, diastolic blood pressure (DBP), body mass index, his-
tory of drinking, and the levels of TC, TG, HDL-C, UA, and
Cr between the two groups were not statistically significant
(p > 0.05; Tables 1 and 2).
Genotype determination
The amplified fragment of the hOGG1 gene was 200 bp, and
it exhibited three genotypes after digestion (Figures 1
and 2). (1) The Ser/Ser homozygote was not cleaved by
Table 2 Comparison of biochemical indicators between
the two groups (x  s).
Item ICM (n Z 246) Control (n Z 246)
TC (mmol/L) 5.2  0.7 5.0  0.9
TG (mmol/L) 1.7  1.1 1.6  1.3
HDL-C (mmol/L) 1.3  0.2 1.3  0.2
LDL-C (mmol/L) 3.1  0.8* 2.8  0.7
UA (mmol/L) 327.9  156.8 317.9  165.3
Cr (mmol/L) 96.3  15.9 91.7  14.6
FBG (mmol/L) 5.5  1.7* 5.1  1.0
hs-CRP (mg/L) 8.0  3.0* 1.1  0.9
8-OHdG (ng/mL) 6.7  1.7* 3.0  0.8
Data are presented as mean  standard deviation.
* Compared with the control group, p < 0.05.
Cr Z creatinine; FBG Z fasting blood glucose; HDL-C Z high-
density lipoprotein cholesterol; hs-CRPZ high-sensitivity C-reac-
tive protein; ICMZ ischemic cardiomyopathy; LDL-CZ low-den-
sity lipoprotein cholesterol; 8-OHdGZ 8-hydroxydeoxyguanosine;
TCZ total cholesterol; TGZ triglycerides; UAZ uric acid.
bp
200
M 1 2 3 4 5 6 7 8 9
Figure 1. Electrophoresis of PCR products. Lanes 1e3,
5e9 Z 10 mL of the sample; Lane 4 Z control (without DNA
template); M Z marker (DNA standards with different relative
molecular weights); PCR Z polymerase chain reaction.
244 Y. Jin et al.Fnu4HI and appeared as a single 200-bp band. (2) The Ser/
Cys heterozygote appeared as a 200-bp band and a 100-bp
band, following restriction digestion. (3) The Cys/Cys ho-
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Figure 2. Electrophoretic results of Fnu4HI-digested prod-
ucts of hOGG1 Ser326Cys gene fragment. 1, 3, 4, 6, 7, 9,
10Z Ser/Cys genotype; 2, 5Z Ser/Ser genotype; 8Z Cys/Cys
genotype; M Z DNA standards with different relative molecu-
lar weights.Comparing genotype frequency distributions and
analyzing ICM risk for different genotypes
There was no difference in the frequency distributions
between the two alleles (c2Z 2.182, pZ 0.140). However,
the distributions of the three genotype frequencies
exhibited significant differences (c2Z 12.388, pZ 0.002).
The Cys/Cys genotype frequency was significantly more
prevalent in the ICM group than it was in the control group,
whereas the Ser/Cys genotype frequency was significantly
less prevalent (c2Z 12.165, p < 0.001). Logistic regression
analysis showed that, compared with the Ser/Cys patients,
patients carrying the Cys/Cys genotype had an increased
risk of ICM [crude OR (OR1) Z 2.3; 95% CI, 1.4e3.7]. By
contrast, the role of Ser/Ser was not obvious (OR1 Z 1.5;
95% CI, 1.0e2.2). After correcting for such confounding
factors as diabetes, family history of CHD, history of
smoking, and levels of LDL-C, FBG, CRP, and 8-OHdG, our
analysis indicated that Cys/Cys was the genotype most
obviously correlated with an increased risk of ICM [OR
adjusted for confounding factors (OR2) Z 2.2; 95% CI,
1.4e3.3]. The role of the Ser/Ser genotype remained un-
certain after the above corrections (OR2 Z 1.4; 95% CI,
0.9e1.9). Logistic regression analysis also showed that
when the Ser/Ser and Ser/Cys genotypes were pooled, the
apparent ICM risk for the Cys/Cys-carrying patients
increased (OR1 Z 2.0; 95% CI, 1.3e3.0). In light of this
analysis, the Cys/Cys genotype is indeed correlated with
the risk of ICM (OR2 Z 1.9; 95% CI, 1.2e2.9; Table 3).
Comparison of serum lipids, CRP, FBG, and 8-OHdG
among different hOGG1 genotypes in the ICM group
and control group
The comparisons showed that, in the ICM group, the serum
levels of LDL-C, CRP, FBG, and 8-OHdG in patients carrying
the Cys/Cys genotype were significantly higher than those
in patients carrying the Ser/Ser or Ser/Cys genotypes
(p < 0.05). In the control group, these indexes have no
significant difference between patients carrying different
hOGG1 genotypes (Table 4).Discussion
Genetic contributions to CHD pathogenesis became a hot
topic among medical researchers in the wake of the Human
Genome Project, and this field continues to benefit from
progress in molecular biology [10e12]. The present study
shows that genetic factors are not the only determinants of
CHD pathogenesis. A variety of other factors, such as oxida-
tive stress and smoking history, play important roles in the
occurrence and development of CHD [13]. Until now, hOGG1
has been considered more relevant to cancers and other
diseases than it has been considered relevant to CHD. Cor-
relations between the Ser326Cys polymorphism of the sev-
enth exon and cancer susceptibility were previously
investigated under the hypothesis that the expression of
hOGG1 was related to its polymorphism. The repair capacity
of hOGG1 326Cys is lower than that of hOGG1 326Ser [7].
Consequently, patients carrying the Cys/Cys genotype might
Table 3 Distributions and comparison of hOGG1 genotypes and allele frequencies.
Genotype ICM, n (%) Control, n (%) OR1 (95% CI) OR2 (95% CI)
Ser/cys 90 (36.6) 123 (50.0) 1.0 1.0
Ser/ser 87 (35.4) 82 (33.3) 1.5 (1.0e2.12) 1.4 (0.9e1.9)
Cys/cys 69 (28.0) * 41 (16.7) 2.3 (1.4e3.7) 2.2 (1.4e3.3)
c2 Z 12.388 p Z 0.002
Ser/ser þ ser/cys 177 (72.0) 205 (83.3) 1.0 1.0
cys/cys 69 (28.0) * 41 (16.7) 2.0 (1.3e3.0) 1.9 (1.2e2.9)
c2 Z 9.181 p Z 0.002
Ser allele 264 (53.7) 287 (58.3) 1.0 1.0
Cys allele 228 (46.3) 205 (41.7) 1.2 (0.9e1.6) 1.2 (0.9e1.5)
c2 Z 2.182 p Z 0.140
* Compared with the control group, p < 0.05.
CI Z confidence interval; ICM Z ischemic cardiomyopathy; OR1 Z crude ORs; OR2 Z ORs were adjusted for confounding factors
(diabetes, history of smoking, family history of coronary heart disease, levels of low-density lipoprotein cholesterol, fasting blood
glucose, C-reactive protein, and 8-hydroxydeoxyguanosine).
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exacerbated by other environmental and lifestyle factors
[14]. With recent advances in molecular biology, correlations
between polymorphisms of DNA repairing genes and the
incidence of CHD have begun to attract attention. Currently,
research correlating the hOGG1 Ser326Cys polymorphism
with CHD susceptibility remains limited to populations within
certain countries and regions [2,8,15]. Xiang et al. [16]
studied the correlations between serum 8-OHdG and the
incidence and severity of CHD. Wang et al. [17] investigated
the possible impact of the Ser326Cys polymorphism on mul-
tivascular CHD susceptibility in Taiwanese populations and
identified similar results. Gokkusu et al. [1] also studied
correlations between the polymorphisms in DNA repairing
genes and CHD. Polymorphisms in hOGG1might contribute to
CHD risk by limiting DNA repair.
We do not find a difference in the distributions of these
two allele frequencies (p Z 0.140); however, the distribu-
tions of the three genotype frequencies differed significantly
(p Z 0.002). The Cys/Cys genotype frequency was signifi-
cantly higher in the ICM group than in the control group,
whereas the Ser/Cys genotype frequency was significantly
lower (p < 0.001). Logistic regression analysis showed that,
compared to patients carrying the Ser/Cys genotype, the
patients carrying the Cys/Cys genotype had an increased ICM
risk. By contrast, the role of Ser/Ser was uncertain. After
correcting for such confounding factors as diabetes, history
of smoking, family history of CHD, and levels of LDL-C, FBG,
CRP, and 8-OHdG, our analysis indicated that patients withTable 4 Comparisons of serum lipids, C-reactive protein, FBG





ICM Ser/Ser þ Ser/Cys 177 5.0  1.7
Cys/Cys 69 5.3  1.0
Control Ser/Ser þ Ser/Cys 205 5.0  0.7
Cys/Cys 41 5.0  1.1
* Compared with the Ser/Ser þ Ser/Cys genotypes, p < 0.05.
FBG Z fasting blood glucose; hs-CRP Z high-sensitivity C-reactive pr
poprotein cholesterol; 8-OHdG Z 8-hydroxydeoxyguanosine; TC Z tothe Cys/Cys genotype have an increased risk of ICM
(OR2 Z 2.2; 95% CI, 1.4e3.3). Pooling the Ser/Ser and Ser/
Cys patient data yielded a relative ICM risk to Cys/Cys pa-
tients that was higher than that predicted under the
assumption that Ser/Ser patients and Ser/Cys patients are
distinct groups. The Cys/Cys genotype is likely associated
with the risk of ICM (OR2Z 1.9; 95% CI, 1.2e2.9).
Patients carrying the Cys/Cys genotype may have a
lower DNA repair capacity than those carrying the Ser/Cys
genotype. Such a difference may indicate that the Cys/Cys
genotype is a risk factor of ICM, whereas the Ser/Cys ge-
notype may protect against ICM. In vitro, the repair ca-
pacity of the 326Cys enzyme variant is about seven times
lower than that of the 326Ser variant [7]. By combining our
analysis of the Ser/Ser genotype and Ser/Cys genotype, we
showed that the calculated ICM risk in the patients with the
Cys/Cys genotype increases approximately two-fold,
consistent with the speculation that the patients carrying
326Ser had a relatively higher repairing capacity.
Whether the hOGG1 Ser326Cys polymorphism influences
the risk of ICM by affecting the expression of other clinical
parameters had not been previously studied in detail. We
compared general clinical parameters between the ICM and
control groups. Prevalence of diabetes, smoking, and fa-
milial CHD, as well as serum levels of LDL-C, FBG, CRP, and
8-OHdG, were significantly higher (p < 0.05) for the ICM
group than these features were for the control group.
Within the ICM group, the serum levels of LDL-C, CRP, FBG,









2.8  0.8 5.6  1.9 7.8  2.0 4.5  0.8
3.2  0.7* 7.1  2.4* 10.1  2.9* 8.7  1.7*
2.7  0.5 5.3  1.1 1.0  0.5 3.1  0.6
3.0  0.4 5.0  0.4 1.2  1.1 2.8  1.2
otein; ICM Z ischemic cardiomyopathy; LDL-C Z low-density li-
tal cholesterol.
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Ser/Cys genotypes (p < 0.05). Research on cancer and
other diseases has previously studied 8-OHdG; more
recently, it has been found to correlate with certain car-
diovascular diseases [18e21]. A high 8-OHdG content was
detected inside human carotid atherosclerotic plaques
[22]. The 8-OHdG level in the DNA extracted from periph-
eral blood lymphocytes was increased for CHD patients, and
positively correlated with disease severity [23]. Oxygen
free radical damage to DNA contributes to diabetes, certain
cancers, CHD, and other major vascular diseases. Autopsies
and coronary angiographies show that type II diabetes often
associates with complex coronary artery diseases, such as
left main branch diseases, multivascular diseases, and
diffuse lesions [24]. Oxidative stress is one of the main
pathogenic causes of the vascular diseases found in type II
diabetes patients [25]. Botto et al. [23] measured DNA
damage and found that compared with a control group, the
levels of 8-OHdG and DNA strand breaks were significantly
higher in CHD patients; moreover, the increased level of 8-
OHdG was positively correlated with the extent and ste-
notic degree of lesions on branches. Furthermore, the DNA
damage was associated with the risk factors for CHD, such
as diabetes and high blood cholesterol levels.
The results of the present study are consistent with the
above findings. ICM prevalence is closely correlated to
smoking; ICM also correlates with the hOGG1 genotype and
serum levels of LDL-C, CRP, FBG, and 8-OHdG. Elevation of
8-OHdG is also related with the age [26], smoking history
[27], presence of hypertension [28], hyperlipidemia [29],
and diabetes status of a patient [30]. Risk factors for
atherosclerosis such as age, hypertension, high cholesterol,
diabetes, smoking, and obesity may be associated with an
increased level of oxidative stress [31]; however, these
associations require further investigation. The status of
high blood sugar would aggravate DNA damage during
conditions of oxidative stress, and disorders of lipid meta-
bolism are often the main factor in atherosclerosis. Pa-
tients with both high blood sugar and disordered lipid
metabolism are at risk of inducing an increase in systemic
reactive oxygen species. The occurrence of such oxidative
stress in these patients, followed by possible endothelial
dysfunction and cardiovascular complications, highlights
the critical role that hOGG1 polymorphisms may play, given
that they are associated with differing DNA repair
capacities.
The polymorphisms of DNA injury repairing genes allow
different individuals to have different DNA injury repairing
abilities. When the hOGG1 gene and protein expression
levels are reduced, DNA repair capacity may be lowered,
resulting in the aggravation of DNA oxidative injuries [32].
The in vitro 8-OH guanine repair activity of the Cys/Cys
genotype is significantly lower than that of the Ser/Ser
genotype [7], consistent with the hypothesis that in-
dividuals carrying the Cys/Cys alleles may have defective
repair abilities. The polymorphisms of hOGG1326Cys cause
insufficient DNA repair capacity, which might lead to the
retention of 8-OHdG. However, the relations between
oxidative stress-related genes, especially DNA injury-
repairing genes, and oxidative stress are still unclear. In
summary, the expression of hOGG1 plays an important role
in repairing DNA oxidative injuries, particularly in the caseof 8-OHdG excise and repair. The polymorphisms of hOGG1
might lead to different DNA injury repairing abilities in
different individuals, as well as differences in genetic sta-
bility. Therefore, the polymorphisms of DNA injury repair-
ing genes are an important factor in the body’s
susceptibility to disease. Polymorphisms of hOGG1 that
affect protein expression would be deleterious, particularly
if the individual carries the Cys/Cys genotype, because the
encoded enzyme exhibits a reduced ability to identify and
excise 8-OHdG from double-stranded DNA. Whenever a DNA
repair gene becomes damaged, there exists the possibility
that the cell suffering this insult will experience a positive-
feedback cascade in the level of DNA damage, in which
fresh damage accumulates faster than it can be repaired.
The resulting acceleration of the mutation rate disturbs cell
physiology, providing a rationale for the association of
hOGG1 polymorphisms with a range of pleiotropic human
diseases, including certain cancers and cardiovascular
conditions. The combined effect of disturbed cellular
physiology with other systemic factors, such as pathological
blood sugar and cholesterol levels, or atherosclerosis, ag-
gravates the situation further, conspiring to increase the
risk of developing ICM. Genetic polymorphisms, as well as
traditionally recognized environmental factors, together
affect the probability that a patient will develop ICM.
As ICM appears to result from an interaction of multiple
risk factors, and because polymorphism in the seventh exon
of hOGG1 is insufficient by itself to explain an individual’s
entire risk, we support the recent proposal to assess the
overall risk factors for CHD. In addition to considering
environmental and lifestyle factors, we recommend taking
into account genetic contributions to ICM susceptibility.
In future research, we hope to expand the sample size
and epidemiologic detail of our analysis. We are particu-
larly interested in refining the sample population consti-
tution, study methods, and ethnic and geographic
differences.References
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